| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ANVSAnnovis Bio, Inc. | 84.81M | 3.20 | -0.00 | -189.15% | ||||
| CLNNClene Inc. | 60.19M | 5.11 | -0.90 | -47.71% | -142.5% | -17.38% | ||
| ABOSAcumen Pharmaceuticals, Inc. | 112.67M | 1.86 | -1.09 | -143.12% | 0.16 | |||
| BHVNBiohaven Ltd. | 1.58B | 11.92 | -1.28 | -198.83% | 0.09 | |||
| IKTInhibikase Therapeutics, Inc. | 200.09M | 1.65 | -1.42 | -100% | -65.37% | 0.00 | ||
| ALECAlector, Inc. | 198.66M | 1.82 | -1.48 | 3.6% | -156.03% | -186.68% | 0.34 | |
| CGTXCognition Therapeutics, Inc. | 121.82M | 1.38 | -1.62 | -76.61% | 0.04 | |||
| ATHEAlterity Therapeutics Limited | 60M | 3.31 | -2.90 | 35.32% | -330.63% | -73.75% | 0.00 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 14.37K | 2K | 7.87K | 349 | 1.2K | 1.56K | 8.14K | 0 | 0 | 0 |
| Revenue Growth % | -0.89% | -0.86% | 2.93% | -0.96% | 2.45% | 0.3% | 4.2% | -1% | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 4.74M | 3.18M | 5.85M | 0 | 10.44M | 0 |
| COGS % of Revenue | - | - | - | - | 3939.53% | 2033.96% | 718.97% | - | - | - |
| Gross Profit | 14.37K | 2K | 7.87K | 349 | -4.73M | -3.18M | -5.84M | 0 | -10.44M | 0 |
| Gross Margin % | 1% | 1% | 1% | 1% | -3938.53% | -2032.96% | -717.97% | - | - | - |
| Gross Profit Growth % | -0.89% | -0.86% | 2.93% | -0.96% | -13575.75% | 0.33% | -0.84% | 1% | - | 1% |
| Operating Expenses | 1.45M | 2.56M | 4.79M | 7.46M | 7.4M | 2.48M | 8.26M | 23.38M | 8.45M | 16.83M |
| OpEx % of Revenue | 100.68% | 1279% | 608.67% | 21405.31% | 6154.29% | 1585.18% | 1015.22% | - | - | - |
| Selling, General & Admin | 682.26K | 1.17M | 1.64M | 2.02M | 2.66M | 2.48M | 3.31M | 7.29M | 6.38M | 6.19M |
| SG&A % of Revenue | 47.49% | 585.76% | 208.33% | 5806.27% | 2214.76% | 1585.32% | 407.11% | - | - | - |
| Research & Development | 763.96K | 1.39M | 3.15M | 5.44M | 4.74M | 3.18M | 4.95M | 16.09M | 7.88M | 10.64M |
| R&D % of Revenue | 53.18% | 693.24% | 400.34% | 15599.04% | 3939.53% | 2033.96% | 608.1% | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -3.18M | 0 | 0 | -5.81M | 0 |
| Operating Income | -1.51M | -2.56M | -4.78M | -7.46M | -12.13M | -5.66M | -8.25M | -23.38M | -18.9M | -16.83M |
| Operating Margin % | -105.19% | -1278% | -607.67% | -21404.32% | -10092.83% | -3618.14% | -1013.64% | - | - | - |
| Operating Income Growth % | 0.26% | -0.69% | -0.87% | -0.56% | -0.63% | 0.53% | -0.46% | -1.83% | 0.19% | 0.11% |
| EBITDA | -1.51M | -2.55M | -4.78M | -7.46M | -12.12M | -5.65M | -8.2M | -23.37M | -18.87M | 2.86M |
| EBITDA Margin % | -104.81% | -1275.52% | -606.99% | -21390.27% | -10085.7% | -3608.09% | -1008.01% | - | - | - |
| EBITDA Growth % | 0.26% | -0.7% | -0.87% | -0.56% | -0.63% | 0.53% | -0.45% | -1.85% | 0.19% | 1.15% |
| D&A (Non-Cash Add-back) | 5.5K | 4.96K | 5.31K | 4.9K | 8.56K | 15.73K | 45.83K | 11.22K | 28.04K | 0 |
| EBIT | -1.51M | -2.56M | -4.78M | -7.46M | -7.4M | -5.66M | -9.37M | -17.78M | -17.84M | 2.86M |
| Net Interest Income | -23.98K | -15.89K | -5.65K | 0 | 0 | 0 | -411.55K | -282.06K | -201.39K | -76.78K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 4.73K | 0 | 0 | 0 |
| Interest Expense | 23.98K | 15.89K | 5.65K | 0 | 0 | 0 | 416.29K | 282.06K | 201.39K | 76.78K |
| Other Income/Expense | -17.28K | -11.82K | -5.65K | 0 | 4.74M | 0 | -1.5M | 5.32M | 1.39M | 19.61M |
| Pretax Income | -1.53M | -2.57M | -4.79M | -7.46M | -7.4M | -5.66M | -9.24M | -18.06M | -17.51M | 2.78M |
| Pretax Margin % | -106.4% | -1283.9% | -608.39% | -21404.32% | -6153.29% | -3618.14% | -1135.63% | - | - | - |
| Income Tax | 0 | 11.82K | 5.65K | 0 | 0 | 0 | 415.02K | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1.04% | 1% | 1% | 1% |
| Net Income | -1.53M | -2.57M | -4.79M | -7.46M | -7.4M | -5.66M | -9.66M | -18.06M | -17.51M | 2.78M |
| Net Margin % | -106.4% | -1283.9% | -608.39% | -21404.32% | -6153.29% | -3618.14% | -1186.62% | - | - | - |
| Net Income Growth % | 0.25% | -0.68% | -0.86% | -0.56% | 0.01% | 0.23% | -0.71% | -0.87% | 0.03% | 1.16% |
| Net Income (Continuing) | -1.53M | -2.57M | -4.79M | -7.46M | -7.4M | -5.66M | -9.79M | -18.06M | -17.51M | 2.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -21.25 | -22.75 | -35.00 | -46.75 | -32.75 | -23.25 | -41.75 | -42.50 | -35.50 | 2.75 |
| EPS Growth % | 0.58% | -0.07% | -0.54% | -0.34% | 0.3% | 0.29% | -0.8% | -0.02% | 0.16% | 1.08% |
| EPS (Basic) | -21.25 | -22.75 | -35.00 | -46.75 | -32.75 | -23.25 | -41.75 | -42.50 | -35.50 | 2.75 |
| Diluted Shares Outstanding | 71.98K | 113.26K | 137.19K | 159.46K | 173.2K | 190.4K | 231.43K | 300.1K | 491.71K | 1.06M |
| Basic Shares Outstanding | 71.98K | 113.26K | 137.19K | 159.46K | 173.2K | 190.4K | 231.42K | 300.1K | 491.71K | 1.04M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.07M | 897.63K | 2.11M | 2.91M | 2.03M | 1.24M | 22.4M | 9.35M | 13.62M | 18.91M |
| Cash & Short-Term Investments | 944.21K | 753.25K | 1.73M | 2.43M | 1.7M | 1.11M | 21.48M | 8.01M | 12.63M | 13.32M |
| Cash Only | 903.21K | 712.04K | 1.69M | 2.39M | 1.66M | 1.03M | 21.43M | 7.96M | 12.6M | 13.29M |
| Short-Term Investments | 41K | 41.2K | 41.41K | 41.62K | 41.83K | 76.72K | 50.69K | 59.46K | 32.36K | 33.05K |
| Accounts Receivable | 9.16K | 6.92K | 2.17K | 1.16K | 0 | 0 | 0 | 0 | 78.64K | 78.03K |
| Days Sales Outstanding | 232.69 | 1.26K | 100.59 | 1.22K | - | - | - | - | - | - |
| Inventory | -53.48K | -34.44K | -36.69K | -40.14K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 65.06K | 39.36K | 43.97K | 53.5K | 74.22K | 78.75K | 768.78K | 571.72K | 228.85K | 47.28K |
| Total Non-Current Assets | 76.87K | 70.2K | 63.52K | 56.85K | 48.29K | 144.23K | 40.83K | 28.65K | 0 | 0 |
| Property, Plant & Equipment | 1.89K | 1.89K | 1.89K | 1.89K | 0 | 99.61K | 5.91K | 435 | 0 | 0 |
| Fixed Asset Turnover | 7.61x | 1.06x | 4.17x | 0.18x | - | 0.02x | 1.38x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 74.98K | 68.31K | 61.64K | 54.96K | 48.29K | 41.62K | 34.92K | 28.21K | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 3K | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 1.15M | 967.82K | 2.17M | 2.97M | 2.07M | 1.38M | 22.44M | 9.38M | 13.62M | 18.91M |
| Asset Turnover | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - | - | - |
| Asset Growth % | 2.91% | -0.16% | 1.24% | 0.37% | -0.3% | -0.33% | 15.2% | -0.58% | 0.45% | 0.39% |
| Total Current Liabilities | 550.76K | 898.39K | 637.45K | 1.81M | 1.68M | 2.4M | 1.17M | 8.68M | 9.35M | 2.22M |
| Accounts Payable | 311.65K | 478.08K | 207.48K | 523K | 465.02K | 557.84K | 517.17K | 4.03M | 7.84M | 1.74M |
| Days Payables Outstanding | - | - | - | - | 35.84 | 63.97 | 32.26 | - | 274.08 | - |
| Short-Term Debt | 118.28K | 89.92K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 17.04K | 165.88K | 0 | 628.79K | 0 | 0 | 0 | 0 | 518.7K | 38.33K |
| Current Ratio | 1.95x | 1.00x | 3.31x | 1.61x | 1.21x | 0.52x | 19.07x | 1.08x | 1.46x | 8.52x |
| Quick Ratio | 2.05x | 1.04x | 3.36x | 1.63x | 1.21x | 0.52x | 19.07x | 1.08x | 1.46x | 8.52x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 14.11M | 2.52M | 516.19K | 204.85K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 4.94M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 9.17M | 2.52M | 516.19K | 204.85K |
| Total Liabilities | 550.76K | 898.39K | 637.45K | 1.81M | 1.68M | 2.4M | 15.28M | 11.2M | 9.87M | 2.42M |
| Total Debt | 118.28K | 120.86K | 0 | 0 | 0 | 0 | 4.94M | 0 | 0 | 0 |
| Net Debt | -784.93K | -591.18K | -1.69M | -2.39M | -1.66M | -1.03M | -16.49M | -7.96M | -12.6M | -13.29M |
| Debt / Equity | 0.20x | 1.74x | - | - | - | - | 0.69x | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -4.65x |
| Interest Coverage | -63.01x | -161.04x | -846.52x | - | - | - | -19.82x | -82.89x | -93.84x | -219.18x |
| Total Equity | 599.98K | 69.43K | 1.53M | 1.16M | 398.12K | -1.02M | 7.16M | -1.82M | 3.75M | 16.49M |
| Equity Growth % | 4.03% | -0.88% | 21.08% | -0.25% | -0.66% | -3.55% | 8.05% | -1.25% | 3.06% | 3.39% |
| Book Value per Share | 8.34 | 0.61 | 11.18 | 7.25 | 2.30 | -5.34 | 30.93 | -6.08 | 7.63 | 15.58 |
| Total Shareholders' Equity | 599.98K | 69.43K | 1.53M | 1.16M | 398.12K | -1.02M | 7.16M | -1.82M | 3.75M | 16.49M |
| Common Stock | 30.47M | 32.71M | 37.47M | 45.22M | 49.03M | 52.74M | 0 | 0 | 0 | 0 |
| Retained Earnings | -38.55M | -42M | -48.02M | -58.19M | -65.59M | -71.25M | -78.64M | -108.66M | -93.47M | -90.69M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 1.39M | 1.48M | 4.15M | 6.13M | 8.88M | 9.14M | -237.63K | -264.52K | -371.18K | -371.18K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.13M | -1.89M | -4.53M | -6.35M | -6.09M | -4.35M | -9.44M | -17.03M | -10.84M | -27.18M |
| Operating CF Margin % | -78.93% | -945.3% | -575.99% | -18197.28% | -5066.28% | -2782.56% | -1160.18% | - | - | - |
| Operating CF Growth % | 0.3% | -0.67% | -1.39% | -0.4% | 0.04% | 0.28% | -1.17% | -0.8% | 0.36% | -1.51% |
| Net Income | -1.53M | -2.57M | -4.79M | -7.46M | -7.4M | -5.66M | -9.4M | -18.06M | -13.21M | 2.78M |
| Depreciation & Amortization | 5.5K | 4.96K | 5.31K | 4.9K | 8.56K | 15.73K | 46.46K | 11.22K | 21.16K | 0 |
| Stock-Based Compensation | 401.56K | 425.25K | 552.11K | 789.21K | 647.39K | 414.51K | 0 | 487.63K | 271.54K | 825.81K |
| Deferred Taxes | -19.64K | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 13.63K | 1.92K | -6.79K | 0 | -171.37K | 92.82K | 1.5M | -4.87M | -868.55K | -19.06M |
| Working Capital Changes | -6.47K | 245.76K | -295.68K | 324.33K | 822.01K | 784.63K | -1.59M | 5.4M | 2.94M | -11.73M |
| Change in Receivables | 0 | 0 | 0 | 0 | -19.55K | 34.63K | -17.57K | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | -303.52K | 331.44K | 0 | 0 | -32.09K | 2.68M | 4.96M | -6.11M |
| Cash from Investing | -29.55K | -153 | -164 | -152 | -208 | -111.88K | 95.93K | -1.98K | -1.35K | -693 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | -108.67K | -6.13K | -1.98K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | 69.44% | 0.75% | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 1 | -208 | -3.21K | 0 | 0 | 0 | 0 |
| Cash from Financing | 2.49M | 1.75M | 5.31M | 6.86M | 5.36M | 3.83M | 25.63M | 6.49M | 17.75M | 27.88M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 94.16K | 3.57K | 53.15K | 1.32M | 5.36M | 3.83M | 0 | 1.52M | 3.6K | 28.04K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -1.13M | -1.89M | -4.53M | -6.35M | -6.09M | -4.46M | -9.45M | -17.04M | -10.84M | -27.18M |
| FCF Margin % | -78.93% | -945.3% | -575.99% | -18197.28% | -5066.28% | -2851.99% | -1160.93% | - | - | - |
| FCF Growth % | 0.3% | -0.67% | -1.39% | -0.4% | 0.04% | 0.27% | -1.12% | -0.8% | 0.36% | -1.51% |
| FCF per Share | -15.75 | -16.71 | -33.04 | -39.80 | -35.16 | -23.44 | -40.83 | -56.77 | -22.05 | -25.68 |
| FCF Conversion (FCF/Net Income) | 0.74x | 0.74x | 0.95x | 0.85x | 0.82x | 0.77x | 0.98x | 0.94x | 0.62x | -9.78x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 87.07K | 201.39K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -760.88% | -767.98% | -597.36% | -555.07% | -951.67% | - | -314.51% | -677.44% | -1815.54% | 27.46% |
| Gross Margin | 100% | 100% | 100% | 100% | -393853.16% | -203296.1% | -71796.88% | - | - | - |
| Net Margin | -10639.79% | -128390% | -60838.5% | -2140431.58% | -615329.37% | -361814.19% | -118662.24% | - | - | - |
| Debt / Equity | 0.20x | 1.74x | - | - | - | - | 0.69x | - | - | - |
| Interest Coverage | -63.01x | -161.04x | -846.52x | - | - | - | -19.82x | -82.89x | -93.84x | -219.18x |
| FCF Conversion | 0.74x | 0.74x | 0.95x | 0.85x | 0.82x | 0.77x | 0.98x | 0.94x | 0.62x | -9.78x |
| Revenue Growth | -89.29% | -86.06% | 293.03% | -95.57% | 244.67% | 30.2% | 420.04% | -100% | - | - |
ProMIS Neurosciences, Inc. (PMN) has a price-to-earnings (P/E) ratio of 3.0x. This may indicate the stock is undervalued or faces growth challenges.
ProMIS Neurosciences, Inc. (PMN) grew revenue by 0.0% over the past year. Growth has been modest.
ProMIS Neurosciences, Inc. (PMN) reported a net loss of $29.3M for fiscal year 2024.
ProMIS Neurosciences, Inc. (PMN) has a return on equity (ROE) of 27.5%. This is excellent, indicating efficient use of shareholder capital.
ProMIS Neurosciences, Inc. (PMN) had negative free cash flow of $27.2M in fiscal year 2024, likely due to heavy capital investments.